Shelter Pharma Limited has officially expanded its nutraceutical portfolio with the launch of its new D3 Cure Capsules, according to a press release filed with BSE on December 15, 2025.
The company, which has been rooted in natural healing practices since 1965, says the product marks a significant step in strengthening its presence in the fast-growing preventive healthcare and wellness segment.
What the product is
As per the press release, D3 Cure Capsules are designed to prevent and treat Vitamin D deficiency, one of the most common nutritional issues worldwide. Vitamin D is essential for:
- Calcium and phosphorus absorption
- Bone and muscle health
- Immune system support
- Mood regulation
- Cardiovascular wellness
The capsule can also aid in managing chronic conditions such as osteoporosis, osteomalacia, rickets, rheumatoid arthritis, and multiple sclerosis.
Why Shelter Pharma launched it
According to the company, the nutraceutical expansion aligns with its strategy of blending traditional herbal expertise with modern R&D and technology, catering to evolving global health demands. The press release notes that the D3 product is part of efforts to strengthen market presence and deliver long-term value to stakeholders.
Investor impact
While the filing does not provide sales forecasts, Shelter Pharma believes the launch will positively contribute to its growth prospects and reinforce its brand in preventive healthcare. Such product additions are typically viewed as margin-accretive within the nutraceutical category.
